Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PACIRA BIOSCIENCES, INC.

(PCRX)
  Report
Delayed Nasdaq  -  04:00 2022-11-30 pm EST
48.25 USD   +1.17%
11/15Sector Update: Health Care Stocks Edge Higher Premarket Tuesday
MT
11/15Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October; Wedbush Maintains Forecast
MT
11/14Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Days
:
Hours
:
Minutes
:
Seconds
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/23/2022 11/25/2022 11/28/2022 11/29/2022 11/30/2022 Date
48.96(c) 49.69(c) 48.92(c) 47.69(c) 48.25 Last
220 700 58 451 227 228 365 561 531 147 Volume
+1.43% +1.49% -1.55% -2.51% +1.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 677 M - -
Net income 2022 47,0 M - -
Net Debt 2022 510 M - -
P/E ratio 2022 49,8x
Yield 2022 -
Sales 2023 777 M - -
Net income 2023 102 M - -
Net Debt 2023 248 M - -
P/E ratio 2023 22,6x
Yield 2023 -
Capitalization 2 188 M 2 188 M -
EV / Sales 2022 3,98x
EV / Sales 2023 3,14x
Nbr of Employees 697
Free-Float 98,9%
More Financials
Company
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company is engaged in advancing a pipeline of products across a range of therapeutic areas that include acute postsurgical pain; acute and chronic osteoarthritis (OA), pain of the knee; low back and other areas; spasticity and stellate ganglion block of the sympathetic nerves. The company is developing interventions to address... 
Sector
Pharmaceuticals
Calendar
11/29 | 02:30pmPresentation
More about the company
Ratings of Pacira BioSciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about PACIRA BIOSCIENCES, INC.
11/15Sector Update: Health Care Stocks Edge Higher Premarket Tuesday
MT
11/15Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October; Wed..
MT
11/14Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October
MT
11/14Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2..
GL
11/14Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2..
GL
11/08Pacira BioSciences to Present at Two Healthcare Conferences in November
GL
11/07BMO Capital Adjusts Price Target on Pacira BioSciences to $60 From $66, Maintains Marke..
MT
11/04HC Wainwright Adjusts Price Target on Pacira BioSciences to $76 From $83, Maintains Buy..
MT
11/04RBC Trims Pacira BioSciences' Price Target to $80 From $82, Keeps Outperform Rating
MT
11/04Wedbush Lowers Pacira BioSciences' Price Target to $88 From $94, Keeps Outperform Ratin..
MT
11/03PACIRA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
11/03Pacira BioSciences Q3 Non-GAAP Net Income Declines, Revenue Rises -- Shares Fall
MT
11/03Transcript : Pacira BioSciences, Inc., Q3 2022 Earnings Call, Nov 03, 2022
CI
11/03Pacira : Q3 Earnings Snapshot
AQ
11/03Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
More news
News in other languages on PACIRA BIOSCIENCES, INC.
11/15Mise à jour sectorielle : Les actions du secteur de la santé son..
11/14Pacira BioSciences annonce une hausse des ventes nettes de produits préliminaires Expar..
11/03Le bénéfice net non conforme aux PCGR de Pacira BioSciences au 3e trimestre diminue, le..
11/03Pacira BioSciences, Inc. annonce ses résultats pour le troisième trimestre et les neuf ..
10/13Pacira BioScience annonce des revenus préliminaires de 167,5 millions de dollars pour l..
More news
Analyst Recommendations on PACIRA BIOSCIENCES, INC.
More recommendations
ETFs positioned on PACIRA BIOSCIENCES, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
SPDR S&P Pharmaceuticals ETF - USD3.57%0.48%United_States
Invesco Dynamic Pharmaceuticals ETF - USD3.4%-0.06%United_States
Invesco S&P SmallCap Health Care ETF - USD2.42%-0.28%United_States
Principal U.S. Small-Cap Multi-Factor ETF - USD0.55%-0.08%United_States
First Trust Small Cap Growth AlphaDEX Fund - USD0.48%-1.28%NC
More ETFs positioned on PACIRA BIOSCIENCES, INC.
Chart PACIRA BIOSCIENCES, INC.
Duration : Period :
Pacira BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PACIRA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 47,69 $
Average target price 73,55 $
Spread / Average Target 54,2%
EPS Revisions
Managers and Directors
David M. Stack Chairman & Chief Executive Officer
Charles A. Reinhart Chief Financial Officer
Roy Winston Chief Medical Officer
Charles Anthony Laranjeira Senior Vice President-Technical Operations
Jonathan Slonin Chief Clinical Officer
Sector and Competitors
1st jan.Capi. (M$)
PACIRA BIOSCIENCES, INC.-20.74%2 188
JOHNSON & JOHNSON2.93%460 384
ELI LILLY AND COMPANY32.42%345 817
ABBVIE INC.16.84%279 679
PFIZER, INC.-16.19%277 803
NOVO NORDISK A/S19.71%276 497